Compare Essex Property Trust, Inc. (ESS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Essex Property Trust, Inc. trades at $269.13 (market cap $17.23B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.4× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ESS | VRTX | |
|---|---|---|
Market Cap | $17.23B | $128.16B |
Volume | 346,109 | 806,603 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $557.96 |
52-Week Low | $239.61 | $407.37 |
Typical Hold Time | 111 Days | 120 Days |
Enterprise Value | $23.82B | $122.29B |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $268.05, down 1.63% with bearish technical signals. The company reported mixed Q2 2026 results, beating FFO estimates but missing EPS expectations. Strong operational performance and litigation resolution provide fundamental support, though high valuation ratios and debt levels present concerns. Recent institutional buying and a $2.59 dividend declaration highlight investor confidence.
Outlook remains cautiously optimistic with a $303.41 consensus price target offering 13% upside. Key risks include earnings volatility, high leverage, and regional economic exposure. The stock presents a balanced opportunity for income-focused investors seeking quality REIT exposure with disciplined risk management.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
